MX2022005371A - Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. - Google Patents

Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.

Info

Publication number
MX2022005371A
MX2022005371A MX2022005371A MX2022005371A MX2022005371A MX 2022005371 A MX2022005371 A MX 2022005371A MX 2022005371 A MX2022005371 A MX 2022005371A MX 2022005371 A MX2022005371 A MX 2022005371A MX 2022005371 A MX2022005371 A MX 2022005371A
Authority
MX
Mexico
Prior art keywords
difluoroacetamide
chlorophenyl
methyl
oxoisoindolin
dioxopiper
Prior art date
Application number
MX2022005371A
Other languages
English (en)
Inventor
Michael Pourdehnad
Jinhong Fan
Daniel W Pierce
Tonia J Buchholz
Tsun-Wen Yao
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2022005371A publication Critical patent/MX2022005371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En este documento se proporcionan métodos para tratar, prevenir, controlar y/o mejorar la hipotensión relacionada con la administración de 2-(4-clorofenil)-N-((2-(2,6- dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2- difluoroacetamida o un estereoisómero o una mezcla de estereoisómeros, sal farmacéuticamente aceptable, tautómero, profármaco, solvato, hidrato, cocristal, clatrato o polimorfo de la misma en un paciente con cáncer, en donde los métodos comprenden administrar una combinación que comprende 2-(4- clorofenil)-N-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida o un estereoisómero o una mezcla de estereoisómeros, sal farmacéuticamente aceptable, tautómero, profármaco, solvato, hidrato, cocristal, clatrato o polimorfo de los mismos y un agonista del receptor de glucocorticoides, un antagonista del receptor de interleucina-1 o un bloqueador de interleucina-1ß.
MX2022005371A 2019-11-05 2020-11-04 Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. MX2022005371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931040P 2019-11-05 2019-11-05
PCT/US2020/058789 WO2021091946A1 (en) 2019-11-05 2020-11-04 Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide

Publications (1)

Publication Number Publication Date
MX2022005371A true MX2022005371A (es) 2022-08-04

Family

ID=75688258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005371A MX2022005371A (es) 2019-11-05 2020-11-04 Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.

Country Status (14)

Country Link
US (1) US20210128545A1 (es)
EP (1) EP4054578A4 (es)
JP (1) JP2022554346A (es)
KR (1) KR20220110494A (es)
CN (1) CN114901281A (es)
AU (1) AU2020379680A1 (es)
BR (1) BR112022008677A2 (es)
CA (1) CA3157196A1 (es)
CL (1) CL2022001190A1 (es)
CO (1) CO2022005861A2 (es)
IL (1) IL292765A (es)
MX (1) MX2022005371A (es)
PE (1) PE20221155A1 (es)
WO (1) WO2021091946A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6871256B2 (ja) 2016-01-08 2021-05-12 セルジーン コーポレイション ２−（４−クロロフェニル）−ｎ−（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル）メチル）−２，２−ジフルオロアセトアミドの製剤
BR112022010019A2 (pt) 2019-12-06 2022-08-16 Celgene Corp Processos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
JP6871256B2 (ja) * 2016-01-08 2021-05-12 セルジーン コーポレイション ２−（４−クロロフェニル）−ｎ−（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル）メチル）−２，２−ジフルオロアセトアミドの製剤
WO2017120415A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3405790B1 (en) * 2016-01-19 2023-06-28 Celgene Corporation Transgenic mouse expressing human cereblon
WO2017214014A1 (en) * 2016-06-06 2017-12-14 Celgene Corporation Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Also Published As

Publication number Publication date
CL2022001190A1 (es) 2022-11-18
KR20220110494A (ko) 2022-08-08
IL292765A (en) 2022-07-01
CN114901281A (zh) 2022-08-12
EP4054578A4 (en) 2023-11-22
PE20221155A1 (es) 2022-07-18
BR112022008677A2 (pt) 2022-07-19
AU2020379680A1 (en) 2022-05-26
CA3157196A1 (en) 2021-05-14
WO2021091946A1 (en) 2021-05-14
JP2022554346A (ja) 2022-12-28
EP4054578A1 (en) 2022-09-14
US20210128545A1 (en) 2021-05-06
CO2022005861A2 (es) 2022-05-20

Similar Documents

Publication Publication Date Title
MX2022005371A (es) Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
MX2019013954A (es) Inhibidores covalentes de kras.
CY1122064T1 (el) Σκευασματα 4-αμινο-2- (2,6-διοξοπιπεριδιν-3-υλο)ισοϊνδολινο-1,3-διονης
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
BR112019003811A2 (pt) composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição
MX2022001410A (es) Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
MX2018015120A (es) Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin- 5-il)metil)-2,2-difluoroacetamida.
NZ749192A (en) Ar+ breast cancer treatment methods
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
MX2019011904A (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos.
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
MX2023001468A (es) Tratamiento de cancer de prostata.
MX2021013817A (es) Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
MX2020013157A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
MX2022011523A (es) Terapia combinada para leucemia mielógena aguda.
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
PE20211818A1 (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
MX2021015827A (es) Antagonista de neurokinin -1.
MX2022010794A (es) Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).
MX2018002487A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.